Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South‐East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial-Reference-Cited by-同舟云学术

Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South‐East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial

Published:2021-08-03 Issue:1 Volume:13 Page:54-64
ISSN:2040-1116
Container-title:Journal of Diabetes Investigation
language:en
Short-container-title:J of Diabetes Invest

Author:

Wada Takashi¹,Mori‐Anai Kazumi²^ORCID,Kawaguchi Yutaka²,Katsumata Hideyuki³,Tsuda Hidetaka²,Iida Mitsutaka²,Arakawa Kenji²^ORCID,Jardine Meg J⁴⁵⁶^ORCID

Affiliation:

1. Department of Nephrology and Laboratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Graduate School of Medical Sciences Kanazawa University Kanazawa Japan

2. Ikuyaku. Integrated Value Development Division Mitsubishi Tanabe Pharma Corporation Tokyo Japan

3. Ikuyaku. Integrated Value Development Division Mitsubishi Tanabe Pharma Corporation Osaka Japan

4. The George Institute for Global Health, UNSW Sydney Australia

5. NHMRC Clinical Trials Center University of Sydney Sydney Australia

6. Concord Repatriation General Hospital Sydney Australia

Publisher

Wiley

Subject

General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdi.13624

Reference30 articles.